Skip to main content
Clinical Trials/EUCTR2005-005534-12-DE
EUCTR2005-005534-12-DE
Active, not recruiting
Not Applicable

randomized double blind placebo controlled study on the efficacy of autologous autovaccine in house dust mite allergy - FIAVS

The Symbio Herborn Group GmbH0 sites24 target enrollmentNovember 23, 2005

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
The Symbio Herborn Group GmbH
Enrollment
24
Status
Active, not recruiting
Last Updated
14 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 23, 2005
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
The Symbio Herborn Group GmbH

Eligibility Criteria

Inclusion Criteria

  • otherwise healthy adults with house dust mite allergy prooven by positive prick test and bronchial provocation (FEV1 decrease \> 20%). Episodic bronchial asthma (GINA 0\-I°). Informed consent.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years)
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • allergies towards ingredients of the autovaccine. Bronchial asthma \> GINA I°, other chronic diseases. Pregnancy.

Outcomes

Primary Outcomes

Not specified

Similar Trials